| NCT02465515Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus | Albiglutide Cardiovascular disease, Type 2 diabetes | Established CVD | Ph 4 | Completed | 607 | Feb 2018 | 7 | results |
| NCT00838903Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 386 | Jan 2012 | 1 | results |
| NCT00839527A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 358 | Jan 2012 | 3 | results |
| NCT00838916A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 337 | Jan 2012 | 4 | results |
| NCT00849056Safety and Efficacy of Albiglutide in Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 331 | Nov 2011 | 1 | results |
| NCT00849017Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 262 | Nov 2011 | 4 | results |
| NCT01098539A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. | Albiglutide Renal impairment, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 218 | Nov 2012 | 2 | results |
| NCT00976391A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine | Albiglutide Type 2 diabetes | HbA1c ≤7% | Ph 3 | Completed | 209 | Oct 2011 | 1 | results |
| NCT01128894A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. | Albiglutide, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 173 | Sep 2011 | 1 | results |
| NCT00518115Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only | Albiglutide, Exenatide Type 2 diabetes | BMI 20-40 | Ph 2 | Completed | 163 | May 2008 | 2 | results |
| NCT02229227Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 157 | Jul 2017 | 1 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| NCT01733758A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Albiglutide, Liraglutide Type 2 diabetes | BMI 17-40 | Ph 3 | Completed | 74 | Jun 2014 | — | results |
| NCT02683746Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 70 | Apr 2017 | 1 | results |
| NCT01777282A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI 17-40 | Ph 3 | Completed | 49 | Jan 2015 | 1 | results |
| NCT02284009Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus | Albiglutide Type 1 diabetes | BMI ≤32 | Ph 2 | Completed | 32 | Oct 2017 | 1 | results |
| NCT01098461Dose Ranging Study of Albiglutide in Japanese Subjects | Albiglutide Type 2 diabetes | BMI 18-35 | Ph 2 | Completed | 30 | May 2011 | 2 | results |
| NCT01357889Pharmacokinetics/Pharmacodynamics of Albiglutide | Albiglutide Type 2 diabetes | BMI 20-45 | Ph 2 | Completed | 30 | Oct 2012 | 1 | results |
| NCT02750930Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects | Albiglutide Type 2 diabetes | — | Ph 4 | Terminated | 27 | Mar 2017 | — | results |
| NCT00938158A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects. | Albiglutide Renal impairment, Type 2 diabetes | HbA1c 6-10.5% | Ph 1 | Completed | 7 | Apr 2011 | 2 | |
| NCT00354536In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | — | Ph 2 | Completed | 5 | Sep 2006 | 1 | |
| NCT03015519A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | HbA1c ≤10% | Ph 3 | Withdrawn | 3 | Apr 2020 | — | |
| NCT02793154An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects | Albiglutide, Exenatide Type 2 diabetes | BMI 2-35 | Ph 4 | Terminated | 2 | Mar 2017 | — | results |
| CER-4-T2DComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | — | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| NCT00537719Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo. | Albiglutide Healthy volunteers | BMI 20-32 | Ph 1 | Completed | 1 | Apr 2008 | 1 | |
| NCT01077505An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide . | Albiglutide Healthy volunteers | BMI 19-30 | Ph 1 | Completed | 1 | Nov 2010 | 2 | |
| NCT01147692A Drug Interaction Study of Simvastatin and Albiglutide | Albiglutide Healthy volunteers | BMI ≤30 | Ph 1 | Completed | 1 | Aug 2010 | 1 | |
| NCT01147718A Drug Interaction Study of Albiglutide and Digoxin | Albiglutide Healthy volunteers | BMI ≤30 | Ph 1 | Completed | 1 | Nov 2010 | 2 | |
| NCT01147731A Drug Interaction Study With Albiglutide and Warfarin | Albiglutide Healthy volunteers | BMI ≤30 | Ph 1 | Completed | 1 | Sep 2010 | 2 | |
| NCT01475734Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes | Albiglutide Obesity / overweight, Type 2 diabetes | BMI 28-40 | Ph 2 | Completed | 1 | Jul 2012 | 2 | results |
| NCT02496221A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects | Albiglutide Healthy volunteers | BMI 2-30 | Ph 4 | Completed | 1 | Oct 2015 | 1 | results |
| NCT02660736Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects | Albiglutide Healthy volunteers | BMI ≥18 | Ph 1 | Completed | 1 | Aug 2016 | 1 | |
| NCT02802514A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects | Albiglutide, Exenatide Healthy volunteers | Healthy volunteers | Ph 4 | Terminated | 1 | Aug 2017 | — | results |
| NCT02846233Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? | Albiglutide, Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥30 | Not applicable | Completed | 1 | Dec 2018 | 3 | results |
| NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Apr 2018 | — | |
| NCT01406262Albiglutide Thorough ECG Study in Healthy Volunteers | Albiglutide Healthy volunteers | BMI 18-30 | Ph 1 | Completed | 0 | Dec 2011 | 1 | |
| NCT02229240Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus | Albiglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Withdrawn | 0 | Dec 2015 | — | |
